PDF(Pubmed)
Abstract：
Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population.
摘要：
甲基氨基乙酰丙酸酯(MAL)是在某些国家被批准与光动力疗法(PDT)一起用于治疗光化性角化病(AK)和野外癌变的局部化合物。AK患者的疾病负担很高：需要重复治疗，已知有进展为角质形成细胞癌的风险，和化妆品外观受到影响。使用MAL进行PDT是一种灵活的治疗策略，可以多种形式使用；红灯，日光,或人造日光可用于照明，所有这些都会导致高AK清除率和低复发率。MAL-PDT方案继续发展，以进一步提高依从性和治疗结果。这里,我们使用PubMed搜索MEDLINE以确定指南，协商一致建议，以及描述使用MAL治疗AK的研究。这篇有针对性的综述的目的是在已发表文献的基础上考虑各种MAL-PDT治疗策略，重点是异质AK人群的个性化治疗。
